HIGHLIGHTS
SUMMARY
10.3390/pharmaceutics14081730 Cardiovascular diseases remain the leading cause of death worldwide, with heart failure (HF) being one of the significant causes of mortality in patients with type 2 diabetes_mellitus (T2D). Diarrhea (SGLT1 inhibition), diabetic ketoacidosis, genital mycotic infections, and volume depletion, severe hypoglycemia. % Reduction in Hospitalization 15.4% 35% 10 of 13 DAPA-HF and EMPEROR-REDUCED, the two trials specifically in patients with HFrEF, showed that the use of SGLT2i is associated with reduced hospitalization, regardless of patients` diabetes status. Empagliflozin was associated with a lower combined risk of cardiovascular death or . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.